Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Institute of Photonics and Electronics, Czech Academy of Sciences, Prague, Czech Republic.
Sci Rep. 2019 Sep 2;9(1):12647. doi: 10.1038/s41598-019-49084-2.
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematological malignancies with a high risk of transformation to acute myeloid leukemia (AML). MDS are associated with posttranslational modifications of proteins and variations in the protein expression levels. In this work, we present a novel interactomic diagnostic method based on both protein array and surface plasmon resonance biosensor technology, which enables monitoring of protein-protein interactions in a label-free manner. In contrast to conventional methods based on the detection of individual biomarkers, our presented method relies on measuring interactions between arrays of selected proteins and patient plasma. We apply this method to plasma samples obtained from MDS and AML patients, as well as healthy donors, and demonstrate that even a small protein array comprising six selected proteins allows the method to discriminate among different MDS subtypes and healthy donors.
骨髓增生异常综合征(MDS)是一组具有高度转化为急性髓系白血病(AML)风险的血液系统恶性肿瘤。MDS 与蛋白质的翻译后修饰和蛋白质表达水平的变化有关。在这项工作中,我们提出了一种新的基于蛋白质阵列和表面等离子体共振生物传感器技术的相互作用组学诊断方法,该方法能够以无标记的方式监测蛋白质-蛋白质相互作用。与基于检测单个生物标志物的传统方法相比,我们提出的方法依赖于测量选定蛋白质阵列与患者血浆之间的相互作用。我们将该方法应用于 MDS 和 AML 患者以及健康供体获得的血浆样本,并证明即使是包含六个选定蛋白质的小蛋白质阵列也可以区分不同的 MDS 亚型和健康供体。